Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 2
1990 2
1991 1
1992 5
1993 9
1994 4
1995 3
1996 2
1997 4
1998 2
1999 12
2000 4
2001 6
2002 3
2003 3
2004 1
2005 1
2006 1
2007 1
2008 4
2009 1
2010 2
2011 1
2012 1
2013 1
2014 3
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 5Brn
Page 1
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. Methods Find Exp Clin Pharmacol. 2004. PMID: 15071612
This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, l-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, …
This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC- …
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Schneider E, Darkin SJ, Lawson PA, Ching LM, Ralph RK, Baguley BC. Schneider E, et al. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1783-90. doi: 10.1016/0277-5379(88)90082-x. Eur J Cancer Clin Oncol. 1988. PMID: 2850193
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (NSC 601316) is a DNA intercalating experimental antitumour agent which is curative against the Lewis lung carcinoma in mice. ...A 1 h drug exposure to 0.85 microM N
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (NSC 601316) is a DNA interc
DNA-Binding Anticancer Drugs: One Target, Two Actions.
Baguley BC, Drummond CJ, Chen YY, Finlay GJ. Baguley BC, et al. Molecules. 2021 Jan 21;26(3):552. doi: 10.3390/molecules26030552. Molecules. 2021. PMID: 33494466 Free PMC article. Review.
A multidisciplinary team was assembled in Auckland, and Professor Denny played a leading role in this approach. Among a large number of drugs developed in the programme, N-[2-(dimethylamino)-ethyl]-acridine-4-carboxamide (DACA), fi …
A multidisciplinary team was assembled in Auckland, and Professor Denny played a leading role in this approach. Among a large number of drug …
Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
Ferguson LR, Hill CM, Baguley BC. Ferguson LR, et al. Eur J Cancer. 1990;26(6):709-14. doi: 10.1016/0277-5379(90)90123-b. Eur J Cancer. 1990. PMID: 2144158
(N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (acridine carboxamide; NSC 601316) is an acridine-derived experimental antitumour agent with curative properties against Lewis lung carcinoma in mice. ...
(N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (acridine carboxamide; NSC 6013
Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide.
Robertson IG, Bland TJ. Robertson IG, et al. Biochem Pharmacol. 1993 May 25;45(10):2159-62. doi: 10.1016/0006-2952(93)90031-q. Biochem Pharmacol. 1993. PMID: 8512597
Oxidation of the experimental anti-tumour agent N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601316; acridine carboxamide) to the 9(10H)acridone, followed by ring hydroxylation and glucuronidation, appea …
Oxidation of the experimental anti-tumour agent N-[(2'-dimethylamino)ethyl]acridine-4-carboxami
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
Finlay GJ, Baguley BC. Finlay GJ, et al. Eur J Cancer Clin Oncol. 1989 Feb;25(2):271-7. doi: 10.1016/0277-5379(89)90019-9. Eur J Cancer Clin Oncol. 1989. PMID: 2702982
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601316) is a chemically novel antitumour agent which is thought to interact with DNA topoisomerase II and which has DNA binding properties which are distinct f
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601316) is a chemic
Methadone: a potent inhibitor of rat liver aldehyde oxidase.
Robertson IG, Gamage RS. Robertson IG, et al. Biochem Pharmacol. 1994 Feb 9;47(3):584-7. doi: 10.1016/0006-2952(94)90192-9. Biochem Pharmacol. 1994. PMID: 8117328
Several drugs with structural similarities to SKF-525A were tested for their ability to inhibit rat liver aldehyde oxidase using the experimental antitumour agent N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC
Several drugs with structural similarities to SKF-525A were tested for their ability to inhibit rat liver aldehyde oxidase using the experim …
Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.
Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Hutchinson OC, et al. Curr Pharm Des. 2003;9(11):917-29. doi: 10.2174/1381612033455288. Curr Pharm Des. 2003. PMID: 12678875 Review.
This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide a …
This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokineti …
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, Matthews JC, Denny WA, Baguley BC, Jones T, Price PM. Osman S, et al. Cancer Res. 1997 Jun 1;57(11):2172-80. Cancer Res. 1997. PMID: 9187117 Clinical Trial.
This study reports on the biodistribution and metabolism of the 11C-labeled novel antitumor agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) (also known as NSC 601316) in rats (plasma and tissues) and hum …
This study reports on the biodistribution and metabolism of the 11C-labeled novel antitumor agent N-[2-(dimethylamino) …
Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative.
Robertson IG, Palmer BD, Officer M, Siegers DJ, Paxton JW, Shaw GJ. Robertson IG, et al. Biochem Pharmacol. 1991 Oct 24;42(10):1879-84. doi: 10.1016/0006-2952(91)90585-s. Biochem Pharmacol. 1991. PMID: 1741765
The acridine antitumor agent N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601316; acridine carboxamide) is oxidized efficiently in vitro by rat and mouse hepatic cytosolic fractions. ...
The acridine antitumor agent N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC
80 results